Drug test firm in AIM debut

A company that has devised an on-the-spot test to detect drug abuse was today set to debut on the London stock market with a value of £27m (€40.5m).

A company that has devised an on-the-spot test to detect drug abuse was today set to debut on the London stock market with a value of £27m (€40.5m).

Cozart, based at Abingdon in Oxfordshire, has forged a close relationship with the British Home Office for the use of its portable RapiScan system in the fight against drugs.

You have reached your article limit. Already a subscriber? Sign in

Save €40 on an Annual Subscription.​

Continue reading within unlimited digital access and exclusive subscriber benefits.

Cancel anytime

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited